Exclusive Online Content
Indivior PLC to Acquire Opiant Pharmaceuticals
Opiant Pharmaceuticals Inc. recently announced it has entered into a definitive merger agreement to be acquired by Indivior Inc, a subsidiary of Indivior PLC (LON: INDV). Under the terms of the agreement,….
IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines….
Minoryx & Neuraxpharm Announce Strategic Alliance to Provide New Therapy for Rare CNS Disease
The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD)….
Insilico Medicine Signs Strategic Research Collaboration With Sanofi Worth up to $1.2 Billion
Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single to low double-digit royalties….
GHO Capital & The Vistria Group to Acquire Alcami From Madison Dearborn Partners & Ampersand Capital Partners
Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact, recently….
Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline
Exelixis, Inc. and Catalent, Inc. recently announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with….
TFF Pharmaceuticals Announces Collaboration With Aptar Pharma to Explore & Develop Intranasal Delivery of Dry Powder Vaccines & Dry Powder Therapeutics
TFF Pharmaceuticals, Inc. recently announced a collaboration with Aptar Pharma aimed at developing and testing the administration of dry powder vaccines utilizing….
Jounce Therapeutics Earns Clinical Milestone Payment Under Exclusive License Agreement With Gilead Sciences
Jounce Therapeutics, Inc. recently announced earning a $15-million clinical milestone payment from Gilead Sciences, Inc. under the exclusive license agreement for….
Acumen Publishes Phase 1 Trial Design & Clinical Development Plan for an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced it published its development rationale and clinical development plan for ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble….
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
Eterna Therapeutics Inc. recently announced it has entered into a sponsored research agreement with Michael Andreeff, MD, PhD, Professor of Leukemia at The University of Texas MD Anderson Cancer Center (MD Anderson)…..
EXCLUSIVE ONLINE CONTENT
Cellares & Bristol Myers Squibb Announce $380-M Worldwide Capacity Reservation & Supply Agreement
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across its IDMO Smart Factories in the US, EU, and Japan for Bristol Myers Squibb’s use ….
Neurolentech Signs Technology Access Partnership With Kaerus Bioscience
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes….
Palisade Bio Enters Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach
Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers….
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….